Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients
The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70–...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550251/ https://www.ncbi.nlm.nih.gov/pubmed/36152043 http://dx.doi.org/10.18632/aging.204299 |
_version_ | 1784805839666675712 |
---|---|
author | Tomas-Grau, Rodrigo Hernán Maldonado-Galdeano, Carolina López, Mónica Aguilar Pingitore, Esteban Vera Aznar, Patricia Alcorta, María Elena del Mar Vélez, Eva María Stagnetto, Agustín Soliz-Santander, Silvana Estefanía Ávila, César Luís Socias, Sergio Benjamín Costas, Dardo Chahla, Rossana Elena Perdigón, Gabriela Chehín, Rosana Nieves Ploper, Diego Cazorla, Silvia Inés |
author_facet | Tomas-Grau, Rodrigo Hernán Maldonado-Galdeano, Carolina López, Mónica Aguilar Pingitore, Esteban Vera Aznar, Patricia Alcorta, María Elena del Mar Vélez, Eva María Stagnetto, Agustín Soliz-Santander, Silvana Estefanía Ávila, César Luís Socias, Sergio Benjamín Costas, Dardo Chahla, Rossana Elena Perdigón, Gabriela Chehín, Rosana Nieves Ploper, Diego Cazorla, Silvia Inés |
author_sort | Tomas-Grau, Rodrigo Hernán |
collection | PubMed |
description | The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70–96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv (p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70–74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19. |
format | Online Article Text |
id | pubmed-9550251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-95502512022-10-11 Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients Tomas-Grau, Rodrigo Hernán Maldonado-Galdeano, Carolina López, Mónica Aguilar Pingitore, Esteban Vera Aznar, Patricia Alcorta, María Elena del Mar Vélez, Eva María Stagnetto, Agustín Soliz-Santander, Silvana Estefanía Ávila, César Luís Socias, Sergio Benjamín Costas, Dardo Chahla, Rossana Elena Perdigón, Gabriela Chehín, Rosana Nieves Ploper, Diego Cazorla, Silvia Inés Aging (Albany NY) Research Paper The early sequencing of the SARS-CoV-2 viral genome allowed for a speedy development of effective vaccines against the virus. Nevertheless, age-related immunosenescence, the inability to mount strong immune responses, still represents a major obstacle. Here, in a group of 149 elderly volunteers (70–96 years old), evolution of the humoral immune response over time to Gam-COVID-Vac (Sputnik V), a vaccine based on heterologous recombinant adenovirus-26 (Ad26) and adenovirus-5 (Ad5) carrying the Spike genome, was analyzed by an anti-RBD ELISA. At 28 days post vaccination (dpv), a seroconversion rate of 91% was achieved, showing the importance of administering at least two doses of Gam-COVID-Vac to elicit a robust immune response, especially in elderly individuals without previous SARS-CoV-2 infection. Interestingly, IgG specific antibodies that reached their highest titers around 28 dpv (median = 740), persisted without significant decrease after 60 dpv (median = 650). After 90 dpv, IgG titers began to drop, and at 180 dpv only 44.7% of the elderly individuals remained with detectable anti-RBD IgG antibodies. No significant differences were observed in specific humoral immune responses between genders at early times point. However, at 60 dpv anti-RBD titers were more persistent in elderly females, and only dropped at 90 dpv (p < 0.0001). As expected, the highest antibodies titers were elicited in the youngest subgroup (70–74 years). Our results show that Gam-COVID-Vac was able to deal with the ageing of the immune system, eliciting a robust immune response in an elderly cohort, which lasted approximately 90 dpv at high levels, and protected against COVID-19. Impact Journals 2022-09-21 /pmc/articles/PMC9550251/ /pubmed/36152043 http://dx.doi.org/10.18632/aging.204299 Text en Copyright: © 2022 Tomas-Grau et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Tomas-Grau, Rodrigo Hernán Maldonado-Galdeano, Carolina López, Mónica Aguilar Pingitore, Esteban Vera Aznar, Patricia Alcorta, María Elena del Mar Vélez, Eva María Stagnetto, Agustín Soliz-Santander, Silvana Estefanía Ávila, César Luís Socias, Sergio Benjamín Costas, Dardo Chahla, Rossana Elena Perdigón, Gabriela Chehín, Rosana Nieves Ploper, Diego Cazorla, Silvia Inés Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients |
title | Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients |
title_full | Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients |
title_fullStr | Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients |
title_full_unstemmed | Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients |
title_short | Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients |
title_sort | humoral immunoresponse elicited against an adenoviral-based sars-cov-2 coronavirus vaccine in elderly patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550251/ https://www.ncbi.nlm.nih.gov/pubmed/36152043 http://dx.doi.org/10.18632/aging.204299 |
work_keys_str_mv | AT tomasgraurodrigohernan humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT maldonadogaldeanocarolina humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT lopezmonicaaguilar humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT pingitoreestebanvera humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT aznarpatricia humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT alcortamariaelena humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT delmarvelezevamaria humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT stagnettoagustin humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT solizsantandersilvanaestefania humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT avilacesarluis humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT sociassergiobenjamin humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT costasdardo humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT chahlarossanaelena humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT perdigongabriela humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT chehinrosananieves humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT ploperdiego humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients AT cazorlasilviaines humoralimmunoresponseelicitedagainstanadenoviralbasedsarscov2coronavirusvaccineinelderlypatients |